Empress Therapeutics was unveiled in Cambridge, MA by Flagship Pioneering. Its core technology is the proprietary Chemilogics platform, which creates drugs by understanding how the genetic code programs cells to produce metabolites, a source of potential small-molecule medicines. The company is building an initial pipeline of drug candidates derived from insights produced by that platform. Flagship Pioneering has made an initial commitment of $50 million to support development of the platform and the company’s early pipeline. The article does not report operating metrics, other investors, or the financing instrument. Near-term plans described focus on advancing the Chemilogics platform and Empress’s initial drug candidates.

Total raised

$50M

Funding rounds

1

Latest round

Equity

Latest activity

Jul 2023